Endocrine Connections (Oct 2022)

Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus

  • Hiroshi Arima,
  • Timothy Cheetham,
  • Mirjam Christ-Crain,
  • Deborah Cooper,
  • Mark Gurnell,
  • Juliana B Drummond,
  • Miles Levy,
  • Ann I McCormack,
  • Joseph Verbalis,
  • John Newell-Price,
  • John A H Wass

DOI
https://doi.org/10.1530/EC-22-0378
Journal volume & issue
Vol. 11, no. 11
pp. 1 – 4

Abstract

Read online

‘What’s in a name? That which we call a rose/By any other name would smell as sweet’ (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare’s implication is that a name is nothing but a word, and it therefore represents a convention with no intrinsic meaning. While this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rationale for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology, and pediatric endocrine societies now proposes changing the name of ‘diabetes insipidus’ to ‘arginine vasopressin deficiency (AVP-D)’ for central etiologies, and ‘arginine vasopr essin resistance (AVP-R)’ for nephrogenic etiologies. This article provides both the historical context and the rationale for this proposed name change.

Keywords